These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21799462)

  • 21. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease.
    Glas J; Stallhofer J; Ripke S; Wetzke M; Pfennig S; Klein W; Epplen JT; Griga T; Schiemann U; Lacher M; Koletzko S; Folwaczny M; Lohse P; Göke B; Ochsenkühn T; Müller-Myhsok B; Brand S
    Am J Gastroenterol; 2009 Jul; 104(7):1737-44. PubMed ID: 19455118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity associated with epirubicin treatments in a large case series of dogs.
    Marrington AM; Killick DR; Grant IA; Blackwood L
    Vet Comp Oncol; 2012 Jun; 10(2):113-23. PubMed ID: 22236353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.
    Low SK; Chung S; Takahashi A; Zembutsu H; Mushiroda T; Kubo M; Nakamura Y
    Cancer Sci; 2013 Aug; 104(8):1074-82. PubMed ID: 23648065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer.
    Calero F; Jimeno J; Rodríguez-Escudero F; Asins Codoner J; Mendana J; Iglesias J; Murillo F; Ugalde F; Armas A; Rementería A
    Eur J Gynaecol Oncol; 1992; 13(1):83-9. PubMed ID: 1547798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

  • 28. Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin.
    Okamoto T; Ogata J; Minami K
    Anesth Analg; 2003 Jul; 97(1):19-20, table of contents. PubMed ID: 12818936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epirubicin seems to cause venous sclerosis.
    Lennan E; Middleton JM; Luken J
    BMJ; 2005 Oct; 331(7522):966. PubMed ID: 16239707
    [No Abstract]   [Full Text] [Related]  

  • 30. Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin.
    Nagata K; Egashira N; Yamada T; Watanabe H; Yamauchi Y; Oishi R
    Support Care Cancer; 2012 May; 20(5):951-5. PubMed ID: 21519948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of differential gene expression related to epirubicin-induced cardiomyopathy in breast cancer patients.
    Peng J; Wang Z; Li Y; Lv D; Zhao X; Gao J; Teng H
    Hum Exp Toxicol; 2020 Apr; 39(4):393-401. PubMed ID: 31823667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
    Schneider BP; Shen F; Gardner L; Radovich M; Li L; Miller KD; Jiang G; Lai D; O'Neill A; Sparano JA; Davidson NE; Cameron D; Gradus-Pizlo I; Mastouri RA; Suter TM; Foroud T; Sledge GW
    Clin Cancer Res; 2017 Jan; 23(1):43-51. PubMed ID: 27993963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy.
    Shitara K; Matsuo K; Oze I; Mizota A; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):301-7. PubMed ID: 20960191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer.
    Fasching PA; Liu D; Scully S; Ingle JN; Lyra PC; Rack B; Hein A; Ekici AB; Reis A; Schneeweiss A; Tesch H; Fehm TN; Heinrich G; Beckmann MW; Ruebner M; Huebner H; Lambrechts D; Madden E; Shen J; Romm J; Doheny K; Jenkins GD; Carlson EE; Li L; Fridley BL; Cunningham JM; Janni W; Monteiro ANA; Schaid DJ; Häberle L; Weinshilboum RM; Wang L
    Clin Cancer Res; 2022 Aug; 28(15):3342-3355. PubMed ID: 35653140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression.
    Magdy T; Arlanov R; Winter S; Lang T; Klein K; Toyoda Y; Ishikawa T; Schwab M; Zanger UM
    Pharmacogenomics; 2013 Sep; 14(12):1433-48. PubMed ID: 24024896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.
    Hamzic S; Wenger N; Froehlich TK; Joerger M; Aebi S; Largiadèr CR; Amstutz U
    Pharmacogenomics J; 2017 Jul; 17(4):319-324. PubMed ID: 27001120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy for breast cancer during pregnancy: is epirubicin safe?
    Mir O; Berveiller P; Rouzier R; Goffinet F; Goldwasser F; Treluyer JM
    Ann Oncol; 2008 Oct; 19(10):1814-5. PubMed ID: 18765465
    [No Abstract]   [Full Text] [Related]  

  • 39. Epirubicin approved for breast cancer treatment.
    Miller JL
    Am J Health Syst Pharm; 1999 Nov; 56(21):2177. PubMed ID: 10565690
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical validation of genetic variants associated with
    Fasching PA; Häberle L; Rack B; Li L; Hein A; Ekici AB; Reis A; Lux MP; Cunningham JM; Ruebner M; Jenkins G; Fridley B; Schneeweiss A; Tesch H; Lichtenegger W; Fehm T; Heinrich G; Rezai M; Beckmann MW; Janni W; Weinshilboum RM; Wang L
    Oncotarget; 2017 Sep; 8(44):78133-78143. PubMed ID: 29100455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.